Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc

Blood (2019) 134 (Supplement_1): 3236.

https://doi.org/10.1182/blood-2019-125963

Published: 2019

Journal Articles

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Tyler Maclay, Joseph Vacca, Casey McComas, Alfredo Castro, Melinda Day, PhD, Kevin Mills, PhD

Blood (2018) 132 (Supplement 1): 3963.

https://doi.org/10.1182/blood-2018-99-119373

Published: 2018

Journal Articles

Black Patients Experience Highest Rates of Specific Cancer-Associated Venous Thromboembolism: A Study Based at a Large Safety-Net Hospital in New England

Nana Oduraa Addo-Tabiri, MD PhD, Rani Chudasama, MD, Rhythm Vasudeva, MBChB, Orly Leiva, MD, Brenda Garcia, MD, Jonathan Ravid, BS, Bunze Tamala, BS, Linda Rosen, MSEE, Mostafa Belghasem, MD PhD, Janice Weinberg, PhD, Ryan Ferguson, MPH, Brett Johnson, PhD, Mary Brophy, MD MPH, Vipul Chitalia, MD PhD

Blood (2018) 132 (Supplement 1): 496.

https://doi.org/10.1182/blood-2018-99-115605

Published: 2018

Journal Articles

Increased Phosphatidylserine-Exposing Microparticles and Their Originating Cells Are Associated with the Coagulation Process in Patients with Oral Squamous Cell Carcinoma

Yingmiao Liu, MD, Cong Zhang, MD, Yan Kou, MD, Lili Zou, MD, Hui Liang, MD, Li Hou, MD, Tao Li, MD, Yan Zhang, MD, Baorong Li, MD, Wenhui Liu, MD, Nan Zuo, MD, Jialan Shi, MD PhD, Tenglong Hu, MD PhD

Blood (2018) 132 (Supplement 1): 1222.

https://doi.org/10.1182/blood-2018-99-115855

Published: 2018

Journal Articles

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Ciara Tierney, BSc, Despina Bazou, BSc, MSc, PhD, Giao Le, BA (Hons), MB BCh, MRCPI, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 3177.

https://doi.org/10.1182/blood-2018-99-110166

Published: 2018

Journal Articles

Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect

Ehsan Malek, MD, Richard Creger, PhD, Merle Kolk, Fahrettin Covut, MD, Richard E Champlin, MD, Brenda W. Cooper, MD, Paolo Caimi, MD, Hillard M Lazarus, MD, Vinita Gupta, MD, Anant Vatsayan, MD MBBS, Qaiser Bashir, MD MBBS, Marcos De Lima, MD, Muzaffar H. Qazilbash, MD

Blood (2017) 130 (Supplement 1): 680.

https://doi.org/10.1182/blood.V130.Suppl_1.680.680

Published: 2017

Journal Articles

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Jonathon B Cohen, MDMS, Andreas Engert, MD, Stephen M Ansell, MD PhD, Anas Younes, MD, Marek Trneny, MD, Kerry J Savage, BSc, MD MSc, Radhakrishnan Ramchandren, MD, Graham Collins, MD PhD, Michelle A. Fanale, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Jan Paul De Boer, MD PhD, Margaret A. Shipp, MD, Armando Santoro, MD, John M Timmerman, MD, Mariana Sacchi, Oumar Sy, PhD, John Kuruvilla, MD

Blood (2017) 130 (Supplement 1): 650.

https://doi.org/10.1182/blood.V130.Suppl_1.650.650

Published: 2017

Journal Articles

Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study

Blood (2017) 130 (Supplement 1): 2579.

https://doi.org/10.1182/blood.V130.Suppl_1.2579.2579

Published: 2017

Journal Articles

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

Sarbajit Mukherjee, MD, Michael Machiorlatti, Bilal Khalid, MD, Gabriel Souza Vidal, MD, Jennifer Holter Charkrabarty, MD, Mohamad A. Cherry, MDMS

Blood (2017) 130 (Supplement 1): 3594.

https://doi.org/10.1182/blood.V130.Suppl_1.3594.3594

Published: 2017

Journal Articles

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Blood (2017) 130 (Supplement 1): 1450.

https://doi.org/10.1182/blood.V130.Suppl_1.1450.1450

Published: 2017

Journal Articles

Identifying Unexpected Inherited Marrow Failure Syndromes in Adults Presenting with Aplastic Anemia, MDS or Solid Tumors

Curtis Lachowiez, MD, Gabrielle Meyers, MD

Blood (2016) 128 (22): 5071.

https://doi.org/10.1182/blood.V128.22.5071.5071

Published: 2016

Journal Articles

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Hind Bennani, PharmD, Véronique Saada, PharmD, Christophe Willekens, MD, Jacques Vargaftig, MD

Blood (2015) 126 (23): 1322.

https://doi.org/10.1182/blood.V126.23.1322.1322

Published: 2015

Journal Articles

Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance

Lorenzo Falchi, MD, Michael Keating, MBBS, Susan Lerner, MS, Xuemei Wang, PhD, Kplola Y Elhor Gbito, MD MPH, Sara S. Strom, PhD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD

Blood (2014) 124 (21): 3323.

https://doi.org/10.1182/blood.V124.21.3323.3323

Published: 2014

Journal Articles

Carma1 Is Important for T-ALL CNS Infiltration and Survival in an Animal Model of T-ALL

Sreenivasa Rao Oruganti, MSc, PhD, Christina Halsey, MDPhD, Savannah Krebsbach, Francois Asperti-Boursin, PhD, Sumit Patel, Ksenia Matlawska-Wasowska, PhD, Stuart S. Winter, MD, Judy Cannon, PhD

Blood (2014) 124 (21): 934.

https://doi.org/10.1182/blood.V124.21.934.934

Published: 2014

Journal Articles

Time to Second Objective Disease Progression (PFS2): An Emerging Clinical Trial Endpoint with Regulatory and Reimbursement Implications

Zacharie Mbanya, MSc, MA, Shkun Chadda, MSc.

Blood (2014) 124 (21): 6005.

https://doi.org/10.1182/blood.V124.21.6005.6005

Published: 2014

Journal Articles

Sub-Clinical Activation of Thrombosis May Predict Survival in Cancer Patients

Anupam Batra, MD, Syed A. Mehdi, MD FACP, Frank Brodzik, PA, Donald Pasquale, MD

Blood (2014) 124 (21): 5075.

https://doi.org/10.1182/blood.V124.21.5075.5075

Published: 2014

Journal Articles

Regulation Of T-ALL Migration By PKCθ and Carma1

Sreenivasa Rao Oruganti, MSc, PhD, Savannah Krebsbach, Francois Asperti-Boursin, PhD, Sumit Patel, Stuart S. Winter, MD, Judy Cannon, PhD

Blood (2013) 122 (21): 4987.

https://doi.org/10.1182/blood.V122.21.4987.4987

Published: 2013

Journal Articles

Role of DNA Methylation of the G 0 /G 1 Switch Gene 2 (G0S2) in the Proliferation of Myeloid Leukemia Cells

Takeshi Yamada, PhD, Chun Shik Park, PhD, Ye Shen, H. Daniel Lacorazza, PhD

Blood (2012) 120 (21): 3520.

https://doi.org/10.1182/blood.V120.21.3520.3520

Published: 2012

Journal Articles

Hematopoietic Stem Cells Have an Intrinsic Expansion Limit

Shanti Rojas-Sutterlin, M.Sc, André Haman, B.Sc., Trang Hoang, PhD

Blood (2012) 120 (21): 4749.

https://doi.org/10.1182/blood.V120.21.4749.4749

Published: 2012

NARROW

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

CYT01B, a Novel RAD51 Inhibitor, Act Synergistically with Both Targeted and Chemotherapeutic Anti-Cancer Agents

Black Patients Experience Highest Rates of Specific Cancer-Associated Venous Thromboembolism: A Study Based at a Large Safety-Net Hospital in New England

Increased Phosphatidylserine-Exposing Microparticles and Their Originating Cells Are Associated with the Coagulation Process in Patients with Oral Squamous Cell Carcinoma

Saliva-Omics in Plasma Cell Disorders — Proof of Concept and Potential As a Non-Invasive Tool for Monitoring Disease Burden and MRD Status

Reducing Gastrointestinal Toxicity Associated with Autologous Transplantation for Multiple Myeloma without Compromising Its Anti-Myeloma Effect

Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study

Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study

Analysis of Outcome of Patients Treated with Anti PD-1/Pdl-1 Therapy According to the Degree of Lymphopenia

Expression of Major Histocompatibility Complex (MHC) Class II, but Not MHC Class I, Predicts Outcome in Patients with Classical Hodgkin Lymphoma (cHL) Treated with Nivolumab (Programmed Death-1 [PD-1] Blockade)

Identifying Unexpected Inherited Marrow Failure Syndromes in Adults Presenting with Aplastic Anemia, MDS or Solid Tumors

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Other Cancers in Long-Term Survivors of Chronic Lymphocytic Leukemia: Incidence and Prognostic Relevance

Carma1 Is Important for T-ALL CNS Infiltration and Survival in an Animal Model of T-ALL

Time to Second Objective Disease Progression (PFS2): An Emerging Clinical Trial Endpoint with Regulatory and Reimbursement Implications

Sub-Clinical Activation of Thrombosis May Predict Survival in Cancer Patients

Regulation Of T-ALL Migration By PKCθ and Carma1

Role of DNA Methylation of the G 0 /G 1 Switch Gene 2 (G0S2) in the Proliferation of Myeloid Leukemia Cells

Hematopoietic Stem Cells Have an Intrinsic Expansion Limit

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only